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Abstract
Purpose: It is known that endothelial cells in the kidney are also strongly VEGF-
dependent. Whether intravitreal drugs can be detected within the glomeruli or affect
VEGF in glomerular podocytes is not known. Therefore, the aim of this pilot study
was to investigate the effects of a single intravitreal injection of aflibercept and
ranibizumab on glomeruli of monkeys.
Methods: The kidneys of eight cynomolgus monkeys, which were intravitreally
injected either with 2 mg of aflibercept or with 0.5 mg of ranibizumab, were
investigated one and seven days after injection. Two animals served as controls.
The distribution of aflibercept, ranibizumab and VEGF was evaluated using anti-Fc-
or anti-F(ab)-fragment and anti-VEGF antibodies respectively. The ratio of stained
area/nuclei was calculated using a semi-quantitative computer assisted method.
Glomerular endothelial cell fenestration was quantified in electron microscopy using
a systematic uniform random sampling protocol and estimating the ratio of
fenestrae per mm.
Results: Compared to the controls, the anti-VEGF stained area/nuclei ratio of the
ranibizumab-treated animals showed no significant changes whereas the stained
areas of the aflibercept-treated monkeys showed a significant decrease post-
treatment. Immune reactivity (IR) against aflibercept or ranibizumab was detected
in aflibercept- or ranibizumab treated animals respectively. The number of
fenestrations of the glomerular endothelial cells has shown no significant
differences except one day after aflibercept injection in which the number was
increased.
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Conclusion: Surprisingly, both drugs could be detected within the capillaries of the
glomeruli. After a single intravitreal injection of aflibercept, VEGF IR in the
podocytes was significantly reduced compared to controls. Ranibizumab injection
had no significant effect on the glomeruli’s VEGF level. Whether this is caused by
aflibercept’s higher affinity to VEGF or because it is used in a higher stoichiometric
concentration compared to ranibizumab remains to be investigated.
Introduction
Vascular endothelial growth factor (VEGF) is a 43- to 46-kd glycoprotein and a
major regulator of physiological and pathological angiogenesis [1]. It increases
vascular permeability and plays a vital role in endothelial cell migration,
proliferation and survival. In the kidney, VEGF is highly expressed in presumptive
as well as in mature podocytes and plays a critical role in glomerular development
and function i.e. to establish the glomerular filtration barrier [2].
Anti-VEGF-agents were first used in cancer treatment with some severe side
effects in consequence of systemic administration. Concerning the kidneys,
proteinuria and hypertension have been reported [3–5]. In addition, thrombotic
microangiopathy, nephrotic syndrome, bowel perforation, haemorrhages, stroke,
myocardial infarction, decreased pulmonary surfactant and delayed wound
healing may occur [6–9].
Also in ophthalmology, excessive angiogenesis is a pathogenic factor in many
diseases. These include diabetic proliferative retinopathy and age-related macular
degeneration (AMD) in adults and retinopathy of prematurity in infants. In the
pathogenesis of wet AMD, VEGF plays an outstanding role as it appears to be
sufficient and essential in both physiological and pathological angiogenesis
[10, 11]. Bevacizumab (Avastin, Genentech/Roche), used in an off-label manner in
ophthalmology, is a full length antibody, as such carries the Fc-fragment and is
therefore kept in circulation by the binding to the neonatal Fc receptor (FcR) [12].
The importance of the FcR for pharmacokinetics of agents containing the Fc
domain was also shown in animal models [13]. Besides good clinical results in
ophthalmologic treatment, adverse effects like arterial thromboembolic events,
hypertension and renal thrombotic microangiopathy were observed [14–17]. Our
group has extensively described the effects of intravitreally injected bevacizumab
on monkey eyes [18–21]. Local ocular effects like reductions in choriocapillaris
fenestrations, alteration of choroidal blood flow [19], formation of immune
complexes and thrombotic microangiopathy [20, 21] have been reported.
Ranibizumab (Lucentis, Genentech/Novartis) was approved in 2006 by the food
and drug administration (FDA) for the treatment of wet AMD after the first off-
label uses of bevacizumab. As a cleavage product of bevacizumab, it only consists
of a Fab fragment and similarly to bevacizumab it blocks the receptor binding
domain of all isoforms of VEGF-A. In contrast to the latter, its modified
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molecular structure aims to avoid immunological reactions. Aflibercept (VEGF
Trap-Eye/Eylea, Regeneron/Bayer) is the latest FDA approved agent for
ophthalmic use. It possesses binding sequences for VEGFR-1 and VEGFR-2 that
were fused to the Fc segment of human IgG1 antibody with a binding affinity that
was 140 times greater than that of ranibizumab and binds to all VEGF-A isoforms,
VEGF-B and PIGF [22].
After intravitreal injection of anti-angiogenic agents, Csaky et al., detected these
substances in the systemic circulation [16] and there is evidence that anti-VEGF
drugs reach the systemic circulation sufficiently to decrease serum VEGF
concentrations [10, 23, 24]. Heiduschka et al. have shown in monkeys that some
2% to 5% of bevacizumab is already in the blood stream one and four days after
intravitreal injection [18]. Bevacizumab with its long serum half-life of 20 days
can lower blood VEGF levels even when intravitreally administrated in an amount
comparable to that achieved with intravenous therapy [10, 25, 26]. This finding
raises the possibility that intravitreally administered bevacizumab may suppress
baseline physiologic VEGF activity. Ranibizumab, in contrast, has a much shorter
serum half-life of 6 hours and its serum levels remain low. Although renal
complications have been reported in only rare cases after intravitreal injections of
ranibizumab or bevacizumab [14, 17, 27–29], the possibility of systemic
complications after intravitreal injections of anti-VEGF agents has to be
considered. Regarding aflibercept, little data concerning systemic effects after
intravitreal injection is available although a clearance from the eye into the
systemic circulation has been shown [30]. Therefore, it is vital to investigate the
effects of anti-VEGF agents in nonhuman primates to establish biologic activity
and adverse effects relevant to humans. This in vivo study was performed in
monkeys as antibody molecules and their interaction with Fc receptors in
monkeys mimic those present in humans [31]. To this aim, we investigated the
effects of a single intravitreal injection of ranibizumab and aflibercept on the
kidneys of eight monkeys on days one and seven after injection. The distribution
of aflibercept and ranibizumab in renal glomeruli was analysed, VEGF levels in
glomeruli and the glomerular endothelial cell fenestrations were quantified.
Note that due to the high costs of experiments, this pilot study only consists of
a small number of animals and the study design does not allow the evaluation of a
great variety of time points.
Materials and Methods
1. Animals and study protocol
Ten cynomolgus monkeys (Macaca fascicularis, aged 3 to 8 years) were raised at
the Covance Laboratories (Muenster, Germany) under standard conditions. All
animals were housed and handled in strict accordance with good animal practice
under supervision of veterinarians in accordance with the German Animal
Welfare Act and were monitored for evidence of disease and changes in attitude,
appetite or behaviour suggestive of illness. Full details are shown in Table 1.
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The naive Cynomolgus fascicularis monkeys are from a closed breeding colony
(Noveprim Mauritius). Tests for TB, B-Virus, SIV, SRV, STLV, are carried out
during export and import quarantine. Additionally tests for TB, B-Virus, SIV,
SRV, STLV are carried out regularly for all animals on site regardless if they are in
studies or not.
Cynomogus monkeys are housed in social groups before and during studies.
The space requirements are according to the EU directive (DIRECTIVE 2010/63/
EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 22
September 2010 on the protection of animals used for scientific purposes).
The animal live under a 12 hour dark light cycle, have ad libidum access to
water and food provided twice daily, lab diet plus fresh fruit. The foremost
enrichment is social housing. Additionally mirrors, wooden trunks, balls are
supplied as a standard. Further enrichment devices are available and made
available on a rotating scheme.
The animal welfare officer on site regularly checks the housing and handling
conditions.
Since animals are housed in groups during the study the individuals are not
randomised to the dose group, but rather a stable group of animals created a long
time before the study.
Both eyes of four animals were intravitreally injected with ranibizumab and
another four animals with aflibercept. The doses of anti-VEGF agents were the
same as clinically used in humans and as provided and recommended by the
manufacturers: 2 mg of aflibercept and 0,5 mg of ranibizumab, respectively.
All injections were carried out in the morning, following slight sedation with
ketamin and diazepam. One and seven days after intravitreal injection, the
animals were sacrificed under general anaesthesia and the kidneys were removed
(except the left kidney of a monkey that was sacrificed on day seven after injection
of aflibercept showing aplasia). The left kidney of each animal was prepared for
immunohistochemistry, specimens of the right kidneys served for electron
microscopy as described below. One untreated monkey sacrificed on day seven
and one monkey injected with aflibercept’s vehicle and sacrificed one day after
injection served as controls. Blood samples were taken before injection (predose)
and on days one and seven after injection. Platelet-poor plasma was prepared by
centrifugation. For injection specifications, ophthalmic examinations as well as
Table 1. Details of the animals used in this study.
Covance Study 8260977 Covance Study 8274007
Species: Cynomolgus monkeys (Macaca fasicularis) Sprecies: Cynomolgus monkey (Macaca fasicularis)
Origin: Mauritius Origin: Mauritius
Age at predose start: 3 to 8 years Age at predose start: 3 to 8 years
Predose body weight: 4 to 12 kg Predose body weight: 4 to 12 kg
Number and sex: 5 healthy male animals Number and sex: 5 healthy male animals
Animal housing: Pair and single, due to the single
control animal
Animal housing: Pair and single, due to the single
control animal
doi:10.1371/journal.pone.0113701.t001
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fixation methods and histological procedures, please see our previous publications
[21, 32].
Ethical Statement
Handling and housing of the animals were only done at Covance Laboratories
GmbH. All animals were housed and handled in strict accordance with good
animal practice under supervision of veterinarians in accordance with the German
Animal Welfare Act and were monitored for evidence of disease and changes in
attitude, appetite or behaviour suggestive of illness. The animals were sacrificed,
and their kidneys were fixed at Covance Laboratories GmbH. The animals were
sacrificed under general anaesthesia, i.e., intramuscular injection of ketamine
hydrochloride followed by an intravenous sodium pentobarbitone (Lethabarb,
Virbac, Australia) overdose. Only the further investigations: electron microscopy
and immunohistochemistry were performed in our lab in Tuebingen. These
investigations did not necessitate approval by an institutional review board.
Covance Laboratories GmbH test facility is fully accredited by the AAALAC. This
study was approved by the local IACUC, headed by Dr. Jo¨rg Luft, and performed
in consideration of the following recommendation:
Commission Recommendation 2007/526/EC on guidelines for the accommo-
dation and care of animals used for experimental and other scientific purposes
(Appendix A of Convention ETS 123).
2. Kidneys samples and fixation
On days one and seven after intravitreal injection, the animals were sacrificed
under general anaesthesia, i.e., intramuscular injection of ketamine hydrochloride
followed by an intravenous sodium pentobarbitone (Lethabarb, Virbac, Australia)
overdose. The kidneys were extracted five minutes post-mortem. The left kidney
of each animal was fixed in paraformaldehyde uncut for immunohistochemistry, a
specimen of the right kidneys was dissected into small cube-like pieces with a
length of 2–3 mm and then fixed in glutaraldehyde (ice cooled) for electron
microscopy (the only available kidney of the monkey described above was
prepared for electron microscopy). The kidneys of the monkey without treatment,
or with aflibercept’s vehicle injection, were handled in the same manner.
3. Immunohistochemistry
Sections (4 mm) were cut from formalin-fixed, paraffin embedded tissue and
mounted on superfrost Plus microscope slides (R. Langenbrinck Labor- u.
Medizintechnik).
The slides were deparaffinised and rehydrated, and heat induced epitope
retrieval in TRIS EDTA (pH 9) using a pressure cooker was performed. After two
washing steps in TBS (0.5% TWEEN) immunohistochemical staining of VEGF
was performed according to the instructions provided by the manufacturer in a
humid chamber. The slides were incubated for 60 min with the primary mouse
Renal Effects of Intravitreally Injected Anti-VEGF Agents
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anti-VEGF antibody (1:50, DAKO, Denmark) at 37 C˚ and then processed using
the DAKO REAL Detection System Alkaline Phosphatase/RED kit rabbit/mouse,
then counterstained with hematoxylin and covered. The same procedure was
performed for immune reactivity analysis against ranibizumab and aflibercept
using respectively a primary mouse antibody against the human IgG-Fab-
fragment (Dianova, 1:100) and a primary mouse antibody against the human IgG-
Fc-fragment (Dianova, 1/150). These samples were used for the quantification and
normalisation of VEGF or ranibizumab/aflibercept stainings.
Additionally an immune reactivity analysis using fluorescent antibodies was
performed. A mouse antibody against the human IgG-Fab-fragment of IgG
(dilution 1:400, Jackson ImmunoResearch) and a goat anti-mouse alexa488
labelled secondary antibody (dilution 1:400, Invitrogen) were used for
ranibizumab staining. Goat anti-human IgG-Fc antibody (dilution 1:200, Novus
Biologicals) and a donkey anti-goat alexa488 labelled secondary antibody
(dilution 1:500, molecular probes) were used for aflibercept staining.
4. Quantification and normalisation of VEGF and ranibizumab/
aflibercept stainings
From each tissue sample, photos from 10 randomly chosen glomeruli-containing
regions were taken using a Zeiss Axioscop microscope with AxioVision image
capture software at a magnification of 400x. On these photos the glomeruli were
defined as the area of interest (aoi). These aoi were isolated using the image j
software. In the next step the nuclei in the aoi were counted using a semi-
quantitative computer assisted method (image j). Then the stained area of each
aoi was determined (Fig. 1). Briefly, the image j program offers a colour
deconvolution plug which splits images into three color-channels and is widely
used for immunohistochemistry analysis [33]. The number of nuclei could be
calculated after the hematoxilin stained areas were isolated using the ‘‘H&E’’ filter
of the color deconvolution plug in. After that ‘‘watershed’’ and ‘‘particle counter’’
algorithms were run for the nuclei count as described by others [34, 35]. This
method was compared with manual counting and was found to be as accurate as
the manual method. For the determination of the stained area we used the colour
deconvolution plug in with the RGB (red, green, blue) filter. The red image was
used for the calculation of the stained area.
For the determination of the background for the stained area determination the
red dye intensity from a control which was treated only with the secondary
antibody and the red dye was set as threshold for the filter settings for the image j
analysis. The ratio of stained area/nuclei was calculated and the statistical analysis
was performed as further described.
5. VEGF-A plasma levels
Blood samples of all monkeys were collected in tubes containing EDTA before
intravitreal injection (predose) and on day one and seven after injection of anti-
Renal Effects of Intravitreally Injected Anti-VEGF Agents
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VEGF agents, and plasma was prepared by centrifugation, transferred to new
tubes and stored at 270 C. Plasma samples were analyzed using commercially
available ELISA kits for human VEGF-A (DVE00) (R&D Systems, Minneapolis,
Minnesota). Briefly, the microtitration plates were coated with monoclonal
antibodies specific for VEGF-A, standards and probes were added, incubated and
washed. Then, an enzyme-linked polyclonal antibody specific for VEGF-A was
added and its substrate solution followed after a second incubation and wash step.
After stopping the colour development, the intensity of colour (Optical Density)
was measured by photospectrometry with the lower detection limit of VEGF-A set
at 30 pg/ml. Calculation of VEGF concentration was performed according to the
manufacturer’s recommendations.
6. Light and electron microscopy
Specimens were postfixed with 1% OsO4 at room temperature in 0.1 M
cacodylate buffer (pH 7.4), en bloc stained with uranyl acetate and lead citrate,
and embedded in Epon after dehydration in a graded series of acetones. Semithin
sections were stained with Toluidine Blue and examined by light microscopy
Figure 1. Semi-quantitative computer assisted method used for the quantification and normalisation
of the VEGF staining. Glomeruli were defined as the area of interest (AOI), and then the AOI were isolated
using the image j software. The nuclei in the AOI were then counted and finally the stained area of each AOI
was determined.
doi:10.1371/journal.pone.0113701.g001
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(Zeiss Axioplan2 imaging, Zeiss, Jena, Germany). For electron microscopy, the
sections were cut ultrathin and analyzed with a Zeiss 902 A electron microscope
(Zeiss, Jena, Germany).
7. Quantification of the glomerular endothelial fenestrations
Under the light microscope at a low magnification (x10) glomeruli were identified
in semi-thin sections and checked on mechanical or fixation artifacts and
pathological features at a higher magnification. Three glomeruli per kidney (six
per time point for ranibizumab and aflibercept, three for controls) with middle to
large diameter and intact bowman’s capsules were chosen and cut ultrathin for
electron microscopy. After examination of the probes at a magnification of 3000
fold, montages of transmission electron micrographs were performed by using the
multiple image arrangements 5 MIAs in order to provide montages of the entire
glomeruli (Fig. 2). The montages consist of overlapping images that were taken
using an image analysis software (iTEM, Olympus Soft Imaging Solutions,
Muenster, Germany). Similarly to a previously described method [36], high-
magnification images were taken from the chosen glomeruli according to a
systematic uniform random sampling protocol (SURS). Starting at the top-most
portion of the glomerular tuft,620000 images were taken moving the position of
the thin section grid with the help of the X and Y grid position control keys. For
this purpose, the grid was moved ten units horizontally taking a picture at each
stop point until the opposite portion of the capsule was reached. Then the
position of the grid was moved 10 units vertically and 5 units to the right or left,
respectively. This procedure was continued until the entire glomerular profile was
scanned through (Fig. S1). After pictures were scanned through for artefacts by a
blinded observer, high- magnification images were used for quantification of
glomerular fenestration using a counting tool of the iTEM software. Only pictures
on which glomerular endothelium was undoubtedly identifiable were analyzed. A
line was drawn and measured along the lamina rara interna of the endothelial
basement membrane adjacent to the fenestrated endothelium and fenestrations
were counted by a single observer under standardised conditions. As capillary
walls can be divided into peripheral and mesangial regions [36], only peripheral
portions where glomerular basement membranes and capillary walls show
parallelism were considered. We found that the quantification in the mesangial
portions is not comparable to the peripheral parts as the predominant amount of
mesangial endothelium is not fenestrated whereas on the other hand there are
parts with increased fenestration (as described as ‘‘alveolus fenestratus
endothelialis’’ by Kondo et al., [37]. Thus, this endothelium is morphologically
not comparable to the single layered endothelium in the peripheral portions so
that applying the same quantification method would not be admissible
(Fig.3A–B). Therefore, the mesangial portions were excluded from the
quantification of the fenestrations.
Renal Effects of Intravitreally Injected Anti-VEGF Agents
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8. Statistical analysis
The ratio of fenestrae per mm was calculated using Microsoft-Office-Excel for each
image considered. Statistical significances for the evaluation of the fenestrae per
mm of the glomerular capillaries and for the quantification of VEGF as well as
ranibizumab/aflibercept were determined by using the Student’s t test from the




1.1. Ranibizumab/aflibercept fluorescence staining.
Kidney sections from the control animal did not show any specific staining in the
glomeruli after staining either with an antibody against the anti-human IgG-Fc
fragment (Fig. 4A) or against the anti-human Fab fragment of IgG (not shown).
Only the erythrocytes within the capillaries showed a weak autofluorescence
(Fig. 4A). After omitting the first antibodies, the same staining pattern as in
Fig. 4A was observed (not shown). One day after aflibercept injection, the
endothelium cell layer and material within the capillaries of many glomeruli were
highly fluorescent (Fig. 4B–C). Occasionally, glomeruli in which only the
endothelium was stained were localised close to others that contained high
amounts of IgG-Fc reactive material within the capillaries (Fig. 4B). Erythrocytes
within the glomeruli were highly fluorescent (Fig. 4C). Seven days after aflibercept
injection, the fluorescent material within the capillaries was fewer and the
fluorescence intensity became weaker (Fig. 4D). One day after ranibizumab
injection, the endothelium cell layer and erythrocytes of most glomeruli became
Figure 2. Example of a montage of transmission electron micrographs by using multiple image
arrangements (MIAs) in order to provide the entire renal glomerulus. These images were taken using the
image analysis software iTEM at the magnification of 63000. Here one day after aflibercept injection.
doi:10.1371/journal.pone.0113701.g002
Renal Effects of Intravitreally Injected Anti-VEGF Agents
PLOS ONE | DOI:10.1371/journal.pone.0113701 November 21, 2014 9 / 20
fluorescent after labelling with an antibody against the human Fab fragment of
IgG (Fig. 4E). However, the specific fluorescence was nearly lost seven days after
injection of ranibizumab (Fig. 4F).
Figure 3. Examples of representative transmission electron micrographs of (A) a fenestrated
glomerular endothelium and of (B) peripheral versus mesangial portions of the glomerular
endothelium (both one day after aflibercept injection). (A) Blood lumen on the upper part, urinary space
on the lower part of the image. The healthy glomerular filtration barrier consists of three layers [6]: the
fenestrated glomerular endothelial cells, the intervening glomerular basement membrane and the podocyte
processes and slit diaphragm. GBM5 glomerular basement membrane, CL5 capillary lumen, POD5
podocyte. Arrows mark glomerular endothelial cells fenestrae (note the absence of diaphragm), asterisks
mark podocyte foot processes, arrowheads mark podocyte slit diaphragm. (B) At this magnification, podocyte
foot processes (asterisks) allow the clear identification of the capillary lumen (CL). In accordance with our
definition, the peripheral portion begins where the endothelium and the glomerular endothelial basement
membrane (GBM) run approximately parallel (marked by arrows). Arrows mark direction into which peripheral
endothelium begins. In between the arrows the mesangium (Mes) and the mesangial portion of the capillary
endothelium (MesE) is located. Note that in the mesangial portion there is no GBM adjacent to the fenestrated
endothelium so that the described counting method is not applicable and the endothelium does not show the
typical single- layered configuration. Magnification 620000.
doi:10.1371/journal.pone.0113701.g003
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1.2 Quantification and normalisation of ranibizumab/aflibercept stainings.
Immune reactivity against aflibercept or ranibizumab was only detected in
aflibercept- or ranibizumab-treated animals respectively and did not show any
significant differences between days one and seven (Fig. 5A–B).
1.3 Quantification and normalisation of VEGF staining.
The anti-VEGF stained area to cells ratio in the aoi of the samples (representing
the mean VEGF level/cell ratio) from the tissue of the ranibizumab-treated
animals showed no significant changes at any of the analysed time points
(486¡55 (day 1) and 451¡66 (day 7)) compared to the untreated control-animal
samples (456¡99). However, the stained area to cells ratio of the tissue-samples
of the aflibercept-treated animals showed a significant decrease one day (383¡85)
after treatment (p,0.05) and an even stronger decrease seven days (233¡41)
after treatment (p,0.0001) compared to the untreated control-animal samples
(456¡99). The levels of VEGF were found to be significantly lower in the
Figure 4. Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated
(B–D) and ranibizumab-treated (E–F) monkeys eyes. In all figures, the asterisks label the spaces of the
Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-
human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak
fluorescence. B) One day after aflibercept injection, the endothelium cell layer and material within the
capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc
region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the
lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the
glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after
aflibercept injection, the fluorescent material within the capillaries (arrowhead) and the fluorescence intensity
of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white
arrow) and erythrocytes (arrowhead and black arrow in the inset) were fluorescent after staining with an
antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) and erythrocytes
(arrowhead) was nearly lost seven days after injection of ranibizumab.
doi:10.1371/journal.pone.0113701.g004
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aflibercept-treated animals on days one (383¡85 vs. 486¡55; p,0.05) and seven
(233¡41 vs. 451¡66; p,0.0001) after treatment as compared to the
corresponding ranibizumab-treated ones. The decrease of the VEGF level from
day one to day seven after treatment was also found to be significant (383¡85 vs.
233¡41; p,0.0001) (Fig. 6).
2. Measurement of VEGF-A165 plasma levels
All doses were below the detectable limit of the assay meaning under 30 pg/ml
(not shown).
3. General examinations by light and transmission electron
microscopy
The biopsies of all the kidneys were first studied by light microscopy and also by
TEM with increasing magnification in order to scan the specimens on artefacts
and pathologic features. None of the glomeruli was sclerotic. The podocyte foot
processes were well-formed and did not show effacement, and a continuous slit
diaphragma could be observed. The glomerular basement membrane (GBM) was
of normal thickness and did not show duplication in all specimens without
widening of the subendothelial space or cellular interposition. The well-defined
glomerular endothelium was flattened though there were slight variations in
thickness without endotheliosis. In all samples, it was mostly adjacent to the
GBM.
The capillary loops were filled with more or less electron-dense serum. The
density difference could be observed in glomeruli of all of the kidneys (Fig. 7).
Figure 5. Quantification and normalisation of aflibercept/ranibizumab staining. Results of the analysis of aoi of glomeruli from kidneys of monkeys one
and seven days after aflibercept (A) or ranibizumab (B) treatment and the corresponding controls, respectively after staining with the anti-Fc-fragment
antibody for aflibercept and the anti-Fab fragment antibody for ranibizumab immune reactivity analysis; t-test against the corresponding control was
performed: ** for p,0.001,*** for p,0.0001.
doi:10.1371/journal.pone.0113701.g005
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4. Quantification of the glomerular endothelial cells fenestrations
In total, 30 glomeruli e.g. three glomeruli per monkey fulfilling the criteria
described above were investigated. The total amount of pictures taken was 4855 of
which 1327 (27.3%) were evaluated. After the ratio of fenestrae per mm was
calculated for each image, the values obtained for the two monkeys of aflibercept
and ranibizumab for each time point were pooled. Student’s test was performed
with values of the untreated monkey as control values and it showed a statistically
significant increase (p,0.05) in the number of fenestrae per mm one day after
aflibercept injection (median: 2.05) compared to all other groups (medians: 1.27
for aflibercept day 7, 1.46 for ranibizumab day 1, 1.29 for ranibizumab day 7 and
1.25 for the untreated group) (Fig. 8). The other conditions did not show any
statistical significance compared to the controls (Fig. 8).
Discussion
In the normal kidney, VEGF is expressed on podocytes. Dysregulation of VEGF
expression within the glomeruli has been associated with a wide range of renal
diseases that may occur within weeks to months after intravitreal administration
of VEGF inhibitors [14, 27]. The dose of anti-VEGF agents used in ophthalmology
is minute compared with that used intravenously, but there is evidence of systemic
absorption and diffuse inhibition of VEGF [14, 17, 38, 39]. Pelle et al., reported a
non diabetic patient with normal kidney function who developed kidney toxicity
after four injections of ranibizumab for the treatment of age-related macular
degeneration [14]. Several studies evaluating the safety and efficacy of intravitreal
Figure 6. Quantification and normalisation of the VEGF staining. Results of the analysis of aoi of
glomeruli from kidneys of monkeys one and seven days after ranibizumab and aflibercept treatment and the
corresponding controls after anti-VEGF staining; t-test against control: * for p,0.05, *** for p,0.0001; t-test
ranibizumab day 1 versus aflibercept day 1 and ranibizumab day 7 versus aflibercept day 7: # for p,0.05,
### for p,0,0001; t-test aflibercept day 1 versus aflibercept day7: +++ for p,0.0001.
doi:10.1371/journal.pone.0113701.g006
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anti-VEGF in diabetic patients have reported renal adverse effects [17, 39, 40].
Georgalas et al., postulated that plasma levels of anti-VEGF could possibly cause
deregulation of VEGF expression in the kidney and cause renal damage. Of course
the fact that the patients were diabetic should be taken into consideration since
such patients are prone to develop renal failure [17]. Previous studies [41] have
shown that intravitreally injected ranibizumab is cleared from the eye into the
circulation with a half-life of approximately three days in monkeys [42] and that
ranibizumab can be found in the serum but the concentrations detected were
considered below the necessary threshold for a sufficient VEGF inhibition [43].
Since ranibizumab is not protected from serum elimination by an Fc-fragment, it
has been suggested that it is rapidly cleared from the circulation via renal
elimination. Our data is in accordance with these studies since indeed
ranibizumab was indeed localised in the glomeruli one and seven days after
intravitreal injection and it did not affect the VEGF level in the glomeruli nor the
number of glomerular endothelial fenestrations. We were unable to measure
plasma VEGF levels since the concentrations were always below the detectable
limit (30 pg/ml) of the assay. Larsson et al., have determined in 80 plasma samples
of healthy humans that the mean value ¡ SD of VEGF was 32¡21 pg/ml [44].
Moreover, the use of serum instead of plasma would be preferable since serum
Figure 7. Examples of transmission electron micrographs used for the quantification of the glomerular
endothelial cells fenestrations. The red line drawn a long lamina rara interna, the length of line is in mm, the
red crosses point out fenestrations. (A) after injection of the vehicle; (B) in the untreated control; (C) one day
after injection of ranibizumab; (D) seven days after injection of ranibizumab; (E) one day after injection of
aflibercept; (F) seven days after injection of aflibercept. Magnification 620000.
doi:10.1371/journal.pone.0113701.g007
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VEGF levels are several fold higher than plasma levels, because platelets express
VEGF and secrete it during blood clotting [45].
Unfortunately we have no data concerning the urinary sediments. It would be
of great interest to analyse them, especially as there are indications that anti VEGF
therapies have influence on the kidneys, and can cause proteinuria and
hypertension [3–5]. The analysis of the urinary sediments will also be an aim of
our further studies.
It has been published that aflibercept, in contrast to bevacizumab, binds VEGF-
A in a 1:1 stoichiometry which remains stable in the circulation [46]. The authors
speculated that because of this stoichiometry and the inert nature of the
complexes, aflibercept is not expected to accumulate in renal glomeruli as has
been found for bevacizumab [46]. The present study shows for the first time that
in reality aflibercept is found in the glomeruli after intravitreal injection and
moreover that it significantly decreases their VEGF level. Whether pathological
alterations were caused by ranibizumab or aflibercept in a different manner or not
is out of the focus of this pilot study. Surprisingly one day after injection,
aflibercept was able to increase the number of glomerular endothelial cells
Figure 8. Box plot representation of the quantification of the fenestrations per mm depending on the
treatment and its duration. Application of the Student’s test showed no significant differences in the number
of fenestrations per mm except one day after aflibercept’s injection where the number was increased
compared to all other groups (*, p,0.05).
doi:10.1371/journal.pone.0113701.g008
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fenestrations compared to the controls or ranibizumab-treated monkeys. Since
the glomerular VEGF level was reduced, we rather expected a reduction or a
stabilisation of the number of fenestrations, as apparent in the choriocapillaris
after intravitreal injection of an anti-VEGF agent [19]. This result suggests a
complex regulation of glomerular endothelial cell fenestrations which is not
completely elucidated. Indeed in contrast to the choriocapillaris, it has been
shown that the fenestration of glomerular capillaries requires the action of TGF-
b1 [47]. Moreover, in systemic endothelial fenestrations, the intracellular
pathways through which VEGF acts to induce fenestrations include a key role for
the fenestral diaphragm protein plasmalemmal vesicle-associated protein-1 (PV-
1). However, the role of PV-1 in glomerular endothelial cell fenestrations is less
clear, not least because of controversy over the existence of glomerular endothelial
cell fenestral diaphragms [48]. Satchell and Braet thought that the glomerular
endothelial cell fenestrations generally do not express PV-1 and, it is generally
asserted, do not possess diaphragms. However, they should note that a number of
observations challenge this position. To some extent, appearance of this feature
may be dependent on the fixation and labelling techniques used, since a
diaphragm is seen in some preparations but not in others. It could be either that
some techniques destroy a very delicate diaphragm or that other techniques result
in an artefactual appearance of a diaphragm, perhaps through condensation/
cross-linking and labelling of glycocalyx, other plasma proteins, or the outer
surface of the glomerular basement membrane. Another careful study demon-
strated that glomerular endothelial cells in the rat adult kidney, apart from a small
fraction, do not furnish diaphragms with their fenestrae; most glomerular
endothelial cells in the immature glomeruli of rat embryos have diaphragmed
fenestrations and the number of glomerular endothelial cells with diaphragmed
fenestrations is increased in the glomeruli of Thy-1.1 nephritis rats, presumably
reflecting a process of restorative remodelling of the glomerular capillary tuft after
injury [49]. Along with the appreciation that the intraglomerular portion of
efferent arterioles and direct tributaries may express fenestrated diaphragm [50],
this goes a long way toward clarifying the position. In our study, the fenestrations
of the glomerular endothelial cells of adult monkeys were clearly not closed by
diaphragms (Fig. 3A) which contrast to those observed in the choriocapillaris and
reported in one of our previous monkey studies (Fig. 6 in [19]). Since the same
technique was used in these two studies, technical artefacts can be excluded. The
glomerular changes observed in our study are not very extensive, but one has to
keep in mind, that in the present model anti-VEGF treatment was given only once
and the animals used have no overt renal pathology. Usually patients with e.g.
diabetic retinopathy get the anti-VEGF treatment on regular basis and as
proliferative diabetic retinopathy is a microvascular disesase, we have to assume in
these patients also microvascular disturbances in the kidney including micro-
albuminuria. Under this condition VEGFA secreted from podocytes is essential to
maintain proper cellular functions [51].
What might happen if VEGFA is affected in a stimulated system is speculative
and should be investigated. This might be a consequence of different antibody
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design. The immune complexes might be inductor of thrombotic microangio-
pathy in the kidney [52]. Caution is needed when patients which might also have
already renal disease get these substances locally, which have definitive systemic
effects.
Conclusions
In conclusion, we showed that intravitreal ranibizumab and aflibercept can escape
from the blood-retinal barrier and are also distributed to distant organ like the
kidneys. Our study demonstrated that a single dose of intravitreally injected
aflibercept already decreases the VEGF level in the glomeruli one and seven days
after treatment whereas ranibizumab did not affect the glomerular VEGF level. In
clinical practice, it is therefore important to monitor patients receiving intravitreal
injection of VEGF inhibitors for possible systemic side-effects, particularly kidney
injury, which may not be immediately apparent. Because of the increasing use of
intravitreal anti-VEGF agents in the treatment of age-related macular degenera-
tion, as well as for other indications such as diabetic retinopathy, further studies
are highly needed to elucidate the effects of repeated anti-VEGF injections on
VEGF concentrations in distant organs.
Supporting Information
Figure S1. Demonstration of the systematic uniform random sampling
protocol (SURS) on a multiple image arrangement (MIA). Transmission
electron microscopy, magnification63000. Probe: Aflibercept day 1, Glomerulus
1. Asterisk marks starting position (first picture), double asterisks mark end
position (last picture), arrows mark direction into which SURS was performed.
doi:10.1371/journal.pone.0113701.s001 (DOCX)
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